Orchestra BioMed Holdings, Inc.
OBIOOrchestra BioMed Holdings, Inc.
NASDAQ
Healthcare
Biotechnology
$4.26
-0.08(-1.8%)
52W $2.35 – $5.35
AI-generated
Orchestra BioMed Holdings, Inc.
Revenue breakdown: Partnership Revenue (96.6%), Product (3.4%).
$249MMkt Cap
$51MRev TTM
-$80MNI TTM
-3.5xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 11, 2026Orchestra BioMed Holdings, Inc. (OBIO) reported FY 2025 total revenue of $33.5M, a 1,169% YoY increase from $2.6M in 2024, driven by $32.9M in partnership revenue from the Terumo Termination and ROFR Agreement, including $10.0M upfront and $7.4M premium on Series A Preferred Stock issuance, plus recognition of remaining $15.4M deferred revenue. Product revenue from FreeHold retractors was stable at...
What Changed Recently
Fundamentals
How The Business Makes Money
Revenue by Segment
Partnership Revenue96.6%($70M)
Product3.4%($2M)
Analyst View
Company Profile
CIK0001814114
ISINUS68572M1062
CUSIP68572M106
Phone215 862 5797
Address150 Union Square Drive, New Hope, PA, 18938, US
SEC EDGAR